ClinicalTrials.gov
public full text
Public Domain
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants
The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired liver function and healthy participants. The side effects and tolerability of pirtobrutinib will also be evaluated. Participation could last about 46 days.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants#1094246
- A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants#908189
- A Study to Evaluate the Relative Bioavailability of Two Different Pimicotinib Capsules in Healthy Subjects#912839
- A Study of Baricitinib in Healthy Participants#1033248
- A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease#1085721
Record · ID 879156
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive